CIAM
SUPN icon

Caitong International Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Caitong International Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-398
Closed -$12.5K – 2491
2025
Q2 		$12.5K Sell
398
-862
-68% -$27.6K 0.01% 643
2025
Q1 		$41.3K Buy
+1,260
New +$44.6K 0.03% 559

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caitong International Asset Management's SUPN Position: Q3 2025 in Review

Caitong International Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 398 shares — an estimated $12.5K sold.

Caitong International Asset Management first reported a position in SUPN in Q1 2025 and held it in 2 quarters. The position peaked at $41.3K in Q1 2025. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Caitong International Asset Management reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Caitong International Asset Management sold 398 Supernus Pharmaceuticals shares in Q3 2025, an estimated $12.5K.
  • Caitong International Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Caitong International Asset Management's Supernus Pharmaceuticals position peaked at $41.3K in Q1 2025.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Caitong International Asset Management's 13F filing for Q3 2025, filed 19 Nov 2025.